Blog

Blood Cancer: AOP Health Announces New Findings in Patients With Polycythemia Vera Published in Medical Journal Leukemia

Sep 19, 2023 | blog

VIENNA — AOP Orphan Pharmaceuticals GmbH (AOP Health) introduced the publication of ultimate outcomes on the not too long ago developed interferon remedy, ropeginterferon alfa-2b, in sufferers with polycythemia vera (PV) within the prestigious journal Leukemia¹. The full publication expands on outcomes introduced on the Annual Meeting of the European Hematology Association. Results of long-term remedy within the CONTINUATION-PV examine present additional proof of the illness modifying capability of ropeginterferon alfa-2b in PV.

“AOP Health has invested in a comprehensive clinical research program for ropeginterferon alfa-2b in PV, which has led to the approval by the health authorities in several countries. We are very proud that our scientific work has contributed to addressing the questions that are important to patients”, says Dr. Rudolf Widman, Founder and Board Member of the AOP Health Group.

Professor Heinz Gisslinger from the Medical University of Vienna, the primary creator of the paper, provides: “Ropeginterferon alfa-2b is already established as an effective first-line treatment for patients with PV. These new results suggest that its potential should be considered when evaluating treatment options.”

Ropeginterferon alfa-2b is a long-acting, mono-pegylated proline interferon (ATC L03AB15). It is run as soon as each 2 weeks initially, or as much as month-to-month following stabilization of hematological parameters.

AOP Health’s pivotal medical improvement program for ropeginterferon alfa-2b contains the research PEGINVERA, PROUD-PV and CONTINUATION-PV. The latter is an open-label, multicenter, section IIIb examine assessing the long-term efficacy and security of ropeginterferon alfa-2b versus hydroxyurea (HU) or greatest obtainable remedy (BAT) in sufferers with high-risk or low-risk PV who beforehand participated within the randomized, managed PROUD-PV examine.

Clinical analysis carried out by AOP Health in Europe since 2010 has led to advertising authorization of BESREMi® for the remedy of PV, first granted by the European Commission in 2019, and thereafter by Switzerland, Liechtenstein, Israel, Bahrain, Taiwan, South Korea, Japan and the USA.

¹ ^{Gisslinger, H., Klade, C., Georgiev, P. et al. Event-free survival in sufferers with polycythemia vera handled with ropeginterferon alfa-2b versus greatest obtainable remedy. Leukemia (2023). https://doi.org/10.1038/s41375-023-02008-6}

About Polycythemia Vera
Polycythemia Vera (PV) is a uncommon most cancers of the blood-building stem cells within the bone marrow leading to a continual enhance of crimson blood cells, white blood cells and platelets. This situation will increase the chance for circulatory problems corresponding to thrombosis and embolism, its signs result in a diminished high quality of life and on the long term could progress to myelofibrosis or remodel to leukemia. While the molecular mechanism underlying PV continues to be topic of intense analysis, present outcomes level to blood-building stem cells within the bone marrow with a set of acquired mutations, an important being a mutant type of JAK2 that make up the malignant clone.

Important PV remedy targets are to attain wholesome blood counts (hematocrit under 45%), enhance high quality of life and to sluggish or delay the development of illness.

About AOP Health
The AOP Health Group incorporates a number of corporations together with AOP Orphan Pharmaceuticals GmbH with its seat in Vienna, Austria (“AOP Health”). The AOP Health Group is the European pioneer for built-in therapies for uncommon illnesses and in vital care. Over the previous 25 years, the Group has turn into a longtime supplier of built-in remedy options working from its headquarters in Vienna, its subsidiaries and consultant places of work all through Europe and the Middle East, in addition to by way of companions worldwide. This improvement has been made attainable by a frequently excessive stage of funding in analysis and improvement on the one hand and a extremely constant and pragmatic orientation in the direction of the wants of all its stakeholders on the opposite – particularly the sufferers and their households in addition to additionally the healthcare professionals treating them.